KOL Perspectives: BTK Inhibitors in RA
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Awareness and potential of BTK inhibitors in RA
› Perceptions of BMS-986142’s Phase IItrial design
› Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during Q2 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data
KOLs were divided over BMS-986142’s ability to achieve ACR70 by Week 12 in a refractory patient population
For the majority of KOLs, poseltinib’s discontinuation had little to no impact on their existing perception of BTK inhibitors in RA
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Lilly
Roche
Merck
AbbVie
Lilly
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.